OP0193 EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS

MLA

F. De Benedetti, et al. “OP0193 EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS.” Annals of the Rheumatic Diseases, vol. 81, May 2022, p. 128.2-128. EBSCOhost, https://doi.org/10.1136/annrheumdis-2022-eular.803.

APA

F. De Benedetti, A. Grom, P. Brogan, C. Bracaglia, M. Pardeo, G. Marucci, D. Eleftheriou, C. Papadopoulou, P. Quartier, J. Anton, R. Frederiksen, V. Asnaghi, & C. de Min. (2022). OP0193 EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS. Annals of the Rheumatic Diseases, 81, 128.2-128. https://doi.org/10.1136/annrheumdis-2022-eular.803

Chicago

F. De Benedetti, A. Grom, P. Brogan, C. Bracaglia, M. Pardeo, G. Marucci, D. Eleftheriou, et al. 2022. “OP0193 EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS.” Annals of the Rheumatic Diseases 81 (May): 128.2-128. doi:10.1136/annrheumdis-2022-eular.803.